This is a global Phase 2 study to evaluate the safety and effectiveness of an investigational study drug (called SHR0302) in adults with moderate to severe alopecia areata.
The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo). This is a dose-ranging study, investigating 3 different dosing regimens. It will be double-blinded, meaning that the sponsor, the study doctors, the staff, and the patients will not know whether a patient is on active study drug (or the dose) or placebo.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
94
Oral tablets taken once daily (QD)
Percentage change from baseline in Severity of Alopecia Tool (SALT) score
Severity of alopecia tool is a quantitative assessment of AA severity based on scalp hair loss
Time frame: week 24
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Quest Dermatology Research
Northridge, California, United States
Moore Clinical Research
Brandon, Florida, United States
Dawes Fretzin Clinical Research
Indianapolis, Indiana, United States
Skin Search of Rochester, Inc
Rochester, New York, United States
Dermatologists of Southwest Ohio
Mason, Ohio, United States
The Skin Wellness Center
Knoxville, Tennessee, United States
Progressive Clinical Research
San Antonio, Texas, United States
St George Dermatology and Skin Cancer Centre
Kogarah, New South Wales, Australia
Novatrials
Kogarah, New South Wales, Australia
Veracity Clinical Research
Woolloongabba, Queensland, Australia
...and 24 more locations